Skip to content

Source filing unavailable

Q1 2016 · —
Revenue$336.01M+8.6% vs Q1 2015−1.4% vs Q4 2015
Net Income$75.81M+7.2% vs Q1 2015−8.4% vs Q4 2015
EPS Diluted$1.21+8.0% vs Q1 2015−8.3% vs Q4 2015
Gross Profit$310,477,000+11.4%
Operating Income$121,162,000+3.8%
Operating Cash Flow$151,654,000+57.1%
Free Cash Flowderived$149,182,000+81.6%
Margins · derived
Gross margin92.4%+2.3 pt vs Q1 2015
Operating margin36.1%−1.7 pt vs Q1 2015
Net margin22.6%−0.3 pt vs Q1 2015

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2016Q1 2015Q1 2014Q1 2013
Revenue$336.01M$309.30M$246.92M$196.24M
Net Income$75.81M$70.70M-$92.65M$43.43M
EPS Diluted$1.21$1.12-$1.58$0.71

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR